title: Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
abstract: OBJECTIVE
  Standardized added metabolic activity (SAM) is a PET parameter for assessing the total metabolic load of malignant processes, avoiding partial volume effects and lesion segmentation. The potential role of this parameter in the assessment of response to chemotherapy and bevacizumab was tested in patients with metastatic colorectal cancer with potentially resectable liver metastases (mCRC).
  
  
  METHODS
  (18)F-FDG PET/CT was performed in 18 mCRC patients with liver metastases before treatment and after five cycles of FOLFOX/FOLFIRI and bevacizumab. Of the 18 patients, 16 subsequently underwent resection of liver metastases. Baseline and follow-up SUVmax, and SAM as well as reduction in SUVmax (∆SUVmax) and SAM (∆SAM) of all liver metastases were correlated with morphological response, and progression-free and overall survival (PFS and OS).
  
  
  RESULTS
  A significant reduction in metabolic activity of the liver metastases was seen after chemotherapy with a median ∆SUVmax of 25.3% and ∆SAM of 94.5% (p = 0.033 and 0.003). Median baseline SUVmax and SAM values were significantly different between morphological responders and nonresponders (3.8 vs. 7.2, p = 0.021; and 34 vs. 211, p = 0.002, respectively), but neither baseline PET parameters nor morphological response was correlated with PFS or OS. Follow-up SUVmax and SAM as well as ∆SAM were found to be prognostic factors. The median PFS and OS in the patient group with a high follow-up SUVmax were 10.4 months and 32 months, compared to a median PFS of 14.7 months and a median OS which had not been reached in the group with a low follow-up SUVmax (p = 0.01 and 0.003, respectively). The patient group with a high follow-up SAM and a low ∆SAM had a median PFS and OS of 9.4 months and 32 months, whereas the other group had a median PFS of 14.7 months and a median OS which had not been reached (p = 0.002 for both PFS and OS).
  
  
  CONCLUSIONS
  (18)F-FDG PET imaging is a useful tool to assess treatment response and predict clinical outcome in patients with mCRC who undergo chemotherapy before liver metastasectomy. Follow-up SUVmax, follow-up SAM and ∆SAM were found to be significant prognostic factors for PFS and OS.
authors: Department of Nuclear Medicine, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium, jeroen.mertens@ugent.be.
authors: Jeroen
authors: J
authors: Mertens
authors: S
authors: S
authors: De Bruyne
authors: N
authors: N
authors: Van Damme
authors: P
authors: P
authors: Smeets
authors: W
authors: W
authors: Ceelen
authors: R
authors: R
authors: Troisi
authors: S
authors: S
authors: Laurent
authors: K
authors: K
authors: Geboes
authors: M
authors: M
authors: Peeters
authors: I
authors: I
authors: Goethals
authors: C
authors: C
authors: Van de Wiele
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab; D002166:Camptothecin / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005472:Fluorouracil; D006801:Humans; D002955:Leucovorin; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009944:Organoplatinum Compounds; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
references: J Nucl Med. 2004 Sep;45(9):1480-7
references: 15347714
references: Cancer Res. 2012 Oct 15;72(20):5145-9; discussion 5150
references: 22952219
references: J Nucl Med. 2009 May;50 Suppl 1:43S-54S
references: 19403879
references: Ann Oncol. 2008 Feb;19(2):348-52
references: 17962202
references: Br J Surg. 1990 Nov;77(11):1241-6
references: 2253003
references: Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1441-8
references: 22699529
references: Br J Surg. 2010 Jul;97(7):1110-8
references: 20632280
references: J Nucl Med. 2011 Jan;52(1):48-55
references: 21149474
references: Ann Oncol. 2009 Jun;20(6):1057-61
references: 19164458
references: Ann Surg Oncol. 2006 May;13(5):668-76
references: 16523369
references: J Nucl Med. 2004 Sep;45(9):1519-27
references: 15347719
references: Phys Med Biol. 2004 Jul 21;49(14):N227-34
references: 15357202
references: Eur J Surg Oncol. 2009 May;35(5):515-20
references: 19200687
references: Q J Nucl Med. 2003 Mar;47(1):8-13
references: 12714949
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: Colorectal Dis. 2012 Feb;14(2):e31-47
references: 21848897
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: Br J Cancer. 2006 Apr 10;94(7):982-99
references: 16538219
references: HPB (Oxford). 2010 Feb;12(1):37-42
references: 20495643
references: J Nucl Med. 2007 May;48(5):771-5
references: 17475966
references: Cancer Treat Rev. 2009 Jun;35(4):309-21
references: 19136215
references: Eur J Nucl Med Mol Imaging. 2013 May;40(5):788-9
references: 23436071
references: J Nucl Med. 2009 May;50 Suppl 1:122S-50S
references: 19403881
references: J Nucl Med. 2009 Nov;50(11):1777-84
references: 19837750
references: Eur J Cancer. 2009 Jan;45(2):248-60
references: 19095437
references: Ann Oncol. 2012 Jul;23(7):1687-93
references: 22112970
references: J Clin Oncol. 2011 May 20;29(15):2011-9
references: 21502544
references: Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1670-2
references: 22968400
references: Radiol Clin North Am. 2005 Jan;43(1):189-204
references: 15693656
references: J Nucl Med. 2007 Jan;48 Suppl 1:36S-44S
references: 17204719
references: Clin Positron Imaging. 1999 May;2(3):159-171
references: 14516540
references: Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):663-72
references: 21225425
references: Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1858-67
references: 22945372
references: Cancer. 2007 Feb 15;109(4):718-26
references: 17238180
references: Eur J Cancer. 2007 Sep;43(14):2037-45
references: 17766104
references: Clin Ther. 2006 Nov;28(11):1779-802
references: 17212999